Some of the new terms included in ICD-O-3 are real tongue-twisters:
Tricilemmocarcinoma is in the basal cell series, 8102/3, and is reportable.
Angiomyofibroblastoma is a benign tumor in the fibroma series.
Adenomyoepithelioma is a benign tumor in the complex mixed and stromal neoplasms.
Ectomesenchymoma is a malignancy in the myomatous tumor series.
Cystadenocarcinofibroma is part of three new codes (8313/3 = clear cell cystadenocarcinofibroma ; 9014/3 = serous cystadenocarcinofibroma; and 9015 = mucinous cystadenocarcinofibroma) and is reportable.
And the winner (at 11 syllables!) is a borderline condition, lymphangioleiomyomatosis.